Previous 10 | Next 10 |
NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction Based on a thorough...
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will particip...
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Fr...
2024-01-09 13:24:45 ET More on NGM Biopharmaceuticals NGM Biopharma jumps on take-private offer Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals ...
Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA ® (pembrolizumab) Aldafermin, an ...
2024-01-02 13:56:40 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...
2023-11-20 11:51:39 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...
-- As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment -- -- ELF, an FDA-approved non-invasive blood...
2023-11-02 17:59:38 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...
--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an oral plenary presentation of data from Phase 2b ALPIN...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...